Ark withdraws EU brain cancer filing for Cerepro and starts strategic review
This article was originally published in Scrip
Executive Summary
Ark Therapeutics has withdrawn the EU filing of its brain cancer gene therapy candidate Cerepro (sitimagene ceradenovec), dropping a previous appeal over a negative opinion from the CHMP. It has at the same time initiated a full strategic review of its business and is in discussions with a number of parties which could lead to an offer being made for the company.